Stock Alert: Pluristem Shares Up 24% In Premarket On FDA Clearance News

Shares of Pluristem Therapeutics Inc. (PSTI) are rising over 24% in pre-market today, after the company announced that the U.S. FDA has cleared the company's Investigational New Drug or IND application for a Phase II study of its PLX cells in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome or ARDS.